Involvement of the Wnt/β-Catenin signaling pathway in the heterogenous nuclear ribonucleoprotein K-driven inhibition of proliferation and migration in head and neck squamous cell carcinoma.
Wnt/β-Catenin
head and neck squamous cell carcinoma
heterogeneous nuclear ribonucleoprotein K
migration
proliferation
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
02
12
2019
accepted:
20
08
2020
entrez:
16
11
2020
pubmed:
17
11
2020
medline:
17
11
2020
Statut:
ppublish
Résumé
The abnormal upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K) expression levels were reported to be involved in the progression of various types of cancer. Therefore, it is hypothesized that hnRNP K may serve as a useful diagnostic marker and antitumor target; however, only a few studies to date have investigated the exact role of hnRNP K in head and neck squamous cell carcinoma (HNSCC) and the potential downstream signaling pathway involved. The present study aimed to identify the roles of hnRNP K in the proliferation and migration of HNSCC, and the possible signaling pathways hnRNP K may be associated with in HNSCC. hnRNP K expression levels in clinical HNSCC samples were analyzed using the Oncomine and UALCAN databases, and its association with the survival of patients with HNSCC was analyzed using the tumor-immune system interactions database. Short hairpin RNA targeting hnRNP K was transfected into the CAL-27 cell line to establish HNSCC cells with stable hnRNP K-knockdown. Cell viability was analyzed using a Cell Counting Kit-8 assay and an absolute count assay, and cell proliferation was measured using 5-ethynyl-2'-deoxyuridine incorporation and colony formation assays. Migratory ability of cells was analyzed using wound healing assay and transwell assay. The growth of xenografts derived from hnRNP K-knockdown cells was also evaluated, and bioinformatics analyses were performed using the Gene Ontology and Kyoto Encyclopedia for Genes and Genomes databases to determine the possible downstream signaling pathways of hnRNP K. Furthermore, the status of the Wnt/β-Catenin signaling pathway in hnRNP K-knockdown cells mediated by small interfering RNA was determined using reverse transcription-quantitative PCR and western blotting. The results revealed that the expression levels of hnRNP K were upregulated in HNSCC cell lines and tissues. Moreover, the upregulation of hnRNP K expression levels was associated with poor survival of patients with HNSCC. The knockdown of hnRNP K also decreased HNSCC cell proliferation and migration, and inhibited tumor growth in nude mice. Bioinformatics analyses identified the Wnt/β-Catenin signaling pathway as a possible downstream signaling pathway of hnRNP K. Knockdown of hnRNP K significantly downregulated the expression levels of Wnt/β-Catenin signaling pathway-related proteins; while with knockdown of hnRNP K and overexpression of β-Catenin, the expression levels of Wnt/β-Catenin signaling pathway-related proteins were partially rescued. In conclusion, the present findings indicated that hnRNP K may serve as a candidate diagnostic biomarker and a promising therapeutic target for HNSCC.
Identifiants
pubmed: 33193854
doi: 10.3892/ol.2020.12257
pii: OL-0-0-12257
pmc: PMC7656118
doi:
Types de publication
Journal Article
Langues
eng
Pagination
394Informations de copyright
Copyright: © Liu et al.
Références
J Biol Chem. 2013 May 24;288(21):15046-56
pubmed: 23564449
J Cell Mol Med. 2017 Jul;21(7):1266-1279
pubmed: 27862976
Front Pharmacol. 2016 Aug 12;7:244
pubmed: 27570510
Int J Cancer. 2009 Sep 15;125(6):1398-406
pubmed: 19548310
Cell Cycle. 2016 Jun 17;15(12):1552-7
pubmed: 27049467
Oral Dis. 2014 Apr;20(3):e42-8
pubmed: 23730900
Cancer Cell. 2015 Oct 12;28(4):486-499
pubmed: 26412324
BMC Cancer. 2009 Jan 12;9:11
pubmed: 19138406
Proc Natl Acad Sci U S A. 2007 May 22;104(21):8983-8
pubmed: 17483488
Oncol Lett. 2014 Apr;7(4):1073-1077
pubmed: 24944671
Cancer Res. 2004 Jan 1;64(1):55-63
pubmed: 14729608
J Hematol Oncol. 2012 Jul 03;5:37
pubmed: 22760167
Oncogene. 2018 Jan 4;37(1):86-94
pubmed: 28869607
Mol Genet Genomic Med. 2019 Oct;7(10):e00867
pubmed: 31429522
Cancer Cell. 2004 Apr;5(4):311-6
pubmed: 15093538
Carcinogenesis. 2017 Mar 1;38(3):321-328
pubmed: 28426877
Oncotarget. 2017 Oct 17;8(61):103364-103374
pubmed: 29262567
Zhonghua Zhong Liu Za Zhi. 2011 Oct;33(10):759-63
pubmed: 22335908
Oncotarget. 2017 Mar 21;8(12):20165-20178
pubmed: 28423622
Hum Pathol. 2011 Mar;42(3):393-402
pubmed: 21194727
Nucleic Acids Res. 2012 Jan;40(Database issue):D109-14
pubmed: 22080510
Gene. 2017 Apr 15;608:49-57
pubmed: 28119088
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Cell Signal. 2006 May;18(5):679-87
pubmed: 16084063
Oral Oncol. 2012 Jun;48(6):516-22
pubmed: 22321252
Asian Pac J Cancer Prev. 2018 Feb 26;19(2):513-519
pubmed: 29480994
Int J Clin Exp Pathol. 2013 May 15;6(6):1060-7
pubmed: 23696923
Med Oncol. 2010 Sep;27(3):673-9
pubmed: 19653139
Neoplasia. 2001 Nov-Dec;3(6):459-68
pubmed: 11774028
Mol Cell Biol. 1992 Jan;12(1):164-71
pubmed: 1729596
Virchows Arch. 2018 Jun;472(6):975-981
pubmed: 29721609
PLoS One. 2015 Dec 29;10(12):e0145769
pubmed: 26713736
Clin Oral Investig. 2014 Jan;18(1):269-76
pubmed: 23494454
Head Neck. 2006 Jul;28(7):639-48
pubmed: 16470875
Genes Chromosomes Cancer. 2018 Dec;57(12):653-664
pubmed: 30144205
Oncol Rep. 2016 Aug;36(2):929-35
pubmed: 27278897
Cell Oncol (Dordr). 2018 Apr;41(2):185-200
pubmed: 29243047
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Ann Surg Oncol. 2010 Oct;17(10):2619-27
pubmed: 20499280
Biochim Biophys Acta. 2006 Apr;1765(2):85-100
pubmed: 16378690
Cancer Lett. 2014 Oct 1;352(2):152-9
pubmed: 25016060
Br J Cancer. 2006 Oct 9;95(7):921-7
pubmed: 16953238
Crit Rev Oncol Hematol. 2019 May;137:57-83
pubmed: 31014516